Mankind Pharma Ltd. (MANKIND) AI Stock Analysis

• Market Cap: ₹1.02T
• Dividend Yield: 0.04%
• Average Volume (3M): 10.08K
• Price to Earnings (P/E): 53.2
• Beta (1Y): 0.58
• Revenue Growth: 21.66%
• EPS Growth: -4.92%
• Country: IN
• Employees: 19,540
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 10.70
• Shares Outstanding: 412,758,480
• 10 Day Avg. Volume: 5,924
• 30 Day Avg. Volume: 10,081
• PEG Ratio: 16.80
• Price to Book (P/B): 6.94
• Price to Sales (P/S): 8.15
• P/FCF Ratio: 50.94
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹3,016.67
• Price Target Upside: 25.45% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 66 Neutral
• Price Target: ₹2,720.00 ▲(13.11% Upside)

Mankind Pharma's strong financial performance is the most significant factor driving the stock score, supported by solid revenue and profit growth. However, the technical analysis indicates mixed signals, and the high P/E ratio raises valuation concerns, which temper the overall score.

Mankind Pharma Ltd. Business Overview & Revenue Model

Company Description

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, and respiratory diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. The company offers its products primarily under the Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar brand names. In addition, it engages in the trading and exporting of pharmaceutical and health care products; manufacturing of packing materials ayurvedic products, packing materials, bulk drugs, and consumer goods; real estate, leasing, and hospitality businesses; and provision of IT services. Mankind Pharma Limited was founded in 1986 and is based in New Delhi, India.

How the Company Makes Money

Mankind Pharma generates revenue primarily through the sale of its pharmaceutical and healthcare products. The company has a robust revenue model that includes direct sales to healthcare providers, retail pharmacies, and hospitals, complemented by a strong export business. Key revenue streams include prescription medications, OTC products, and nutraceuticals. Additionally, Mankind engages in strategic partnerships and collaborations with other pharmaceutical companies and distributors, enhancing its market reach and product offerings. The company's focus on innovation and expanding its product portfolio, particularly in high-demand therapeutic areas, significantly contributes to its earnings.

Mankind Pharma Ltd. Financial Statement Overview

Summary

Mankind Pharma has demonstrated strong financial performance with robust revenue growth and impressive profit margins. The company maintains effective operational efficiency and sound cash flow management, supported by a stable balance sheet with low leverage.

Income Statement

Mankind Pharma has shown robust revenue growth with a significant increase of 18.14% in 2025 compared to 2024. The company's gross profit margin remains strong at 71.41%, and the net profit margin is healthy at 16.31%. EBIT and EBITDA margins are impressive at 49.37% and 24.73%, respectively, showcasing effective operational efficiency.

Balance Sheet

The debt-to-equity ratio is well managed at 0.59, indicating prudent leverage. Return on equity is commendable at 13.89%, reflecting efficient use of equity capital. The equity ratio is strong at 51.62%, ensuring financial stability and low risk. The company's balance sheet reflects a solid financial position with a strong equity base.

Cash Flow

The company exhibits a sound cash flow position with a free cash flow growth rate of 10.32%. The operating cash flow to net income ratio stands at 1.21, demonstrating good cash flow generation capability. The free cash flow to net income ratio is also robust at 0.98, indicating strong cash flow relative to net earnings.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	129.56B	122.07B	103.35B	87.43B	77.82B	62.14B
Gross Profit	84.65B	87.18B	70.14B	33.88B	53.12B	43.89B
EBITDA	34.10B	30.18B	28.09B	20.27B	21.47B	18.17B
Net Income	18.93B	19.91B	19.13B	12.82B	14.33B	12.65B
Balance Sheet
Total Assets	0.00	277.60B	119.63B	97.15B	91.48B	63.73B
Cash, Cash Equivalents and Short-Term Investments	25.25B	22.45B	34.56B	15.29B	12.79B	20.04B
Total Debt	0.00	85.11B	2.07B	1.70B	8.73B	2.41B
Total Liabilities	-145.68B	131.91B	23.87B	20.67B	28.31B	15.10B
Stockholders Equity	145.68B	143.32B	93.63B	74.35B	61.55B	47.22B
Cash Flow
Free Cash Flow	0.00	19.53B	17.70B	9.53B	-14.26B	8.25B
Operating Cash Flow	0.00	24.13B	21.52B	17.85B	9.20B	11.37B
Investing Cash Flow	0.00	-126.92B	-20.82B	-10.54B	-13.69B	-12.22B
Financing Cash Flow	0.00	102.33B	52.66M	-7.40B	6.05B	-78.11M

Mankind Pharma Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2404.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MANKIND, the sentiment is Negative. The current price of 2404.7 is below the 20-day moving average (MA) of 2447.47, below the 50-day MA of 2509.81, and below the 200-day MA of 2467.92, indicating a bearish trend. The MACD of -23.81 indicates Negative momentum. The RSI at 45.39 is Neutral, neither overbought nor oversold. The STOCH value of 23.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MANKIND.

Mankind Pharma Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUROPHARMA	―	₹630.26B	18.58	―	0.36%	7.76%	-2.84%
CIPLA	―	₹1.27T	23.63	―	0.82%	6.40%	25.27%
ZYDUSLIFE	―	₹993.45B	21.73	―	1.10%	14.52%	9.46%
LUPIN	―	₹877.48B	23.70	―	0.62%	12.40%	63.16%
TORNTPHARM	―	₹1.21T	60.49	―	0.89%	7.63%	15.39%
MANKIND	―	₹1.02T	53.21	―	0.04%	21.66%	-4.92%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Mankind Pharma Ltd. Corporate Events

Mankind Pharma Reports No Share Dematerialisation Requests for Q3 2025

Mankind Pharma Limited has announced that it has not received any requests for dematerialisation or rematerialisation of shares for the quarter ending September 30, 2025. This update, certified by KFin Technologies Limited, aligns with the company’s adherence to SEBI (Depositories and Participants) Regulations, 2018, ensuring transparency and compliance in its share management practices.

Mankind Pharma Ltd. Sees Withdrawal of CGST Penalty

Mankind Pharma Ltd. announced that the penalty of ₹2,90,70,363 imposed by the CGST Commissionerate, Meerut, for the financial years 2017-18 to 2021-22, has been withdrawn following an appeal. This development is likely to have a positive impact on the company’s financial standing and may enhance its reputation among stakeholders by demonstrating effective legal and regulatory compliance.

Mankind Pharma to Engage with Investors at Jefferies India Forum

Mankind Pharma Ltd. has announced its participation in the upcoming Jefferies 4th India Forum, scheduled for September 17, 2025, in Gurugram. The event will include one-on-one and group meetings, allowing the company’s management to engage with investors. This participation underscores Mankind Pharma’s proactive approach to investor relations and its commitment to transparency, although no unpublished price-sensitive information will be disclosed during the conference.

Mankind Pharma Receives ‘Adequate’ ESG Rating from Crisil

Mankind Pharma Ltd. has received an ESG rating of ‘Crisil ESG 57’ from Crisil ESG Ratings & Analytics Limited, indicating an ‘adequate’ level of environmental, social, and governance practices. This rating reflects the company’s efforts in maintaining transparency and responsibility in its operations, potentially impacting its reputation and attractiveness to investors focused on sustainable practices.

Mankind Pharma Releases Q1 FY26 Investor Call Transcript

Mankind Pharma Ltd. released the transcript of its Q1 FY26 investor conference call, highlighting the company’s financial performance and strategic direction. The call, led by key executives, provided insights into the company’s operations and market positioning, potentially impacting stakeholders’ perspectives on its future growth and industry influence.

Mankind Pharma Seeks Reclassification of Promoter Group

Mankind Pharma Ltd. has submitted an application to reclassify Ayushi and Poonam Estates LLP from the ‘Promoter & Promoter Group’ category to the ‘Public’ category. This move is part of the company’s strategic efforts to align with regulatory requirements and potentially enhance its market positioning by broadening its public shareholder base.